SCHEMBL6841640

SCHEMBL6841640

COC(=O)c1cc(C=Cc2ccncc2)cc(C(=O)OC)c1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 6/20 0.53
CYP1A1 P04798 4/20 0.53
CYP1B1 Q16678 4/20 0.53
KDM1A O60341 1/20 0.51
HDAC1 Q13547 1/20 0.51
HDAC6 Q9UBN7 1/20 0.51
PTPN1 P18031 1/20 0.50
ALOX5 P09917 1/20 0.49
CYP2D6 P10635 4/20 0.47
KDM4E B2RXH2 3/20 0.47
HPGD P15428 2/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
CYP2C19 P33261 2/20 0.47
NPC1 O15118 1/20 0.47
CYP3A4 P08684 1/20 0.47
CYP2C9 P11712 1/20 0.47
RAB9A P51151 1/20 0.47
MAPT P10636 2/20 0.47
SNCA P37840 1/20 0.47
ALDH1A1 P00352 4/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7981695 0.86 KDM1A (0.64) CYP1A2CYP1A1CYP1B1KDM1AHDAC1
SCHEMBL7975552 0.86 KDM1A (0.64) CYP1A2CYP1A1CYP1B1KDM1AHDAC1
SCHEMBL7975551 0.86 KDM1A (0.64) CYP1A2CYP1A1CYP1B1KDM1AHDAC1
SCHEMBL22887220 0.86 P4HB (0.57) CYP1A2CYP1A1CYP1B1KDM1AHDAC1
SCHEMBL22887222 0.86 P4HB (0.57) CYP1A2CYP1A1CYP1B1KDM1AHDAC1
SCHEMBL16749652 0.86 CA12 (0.56) PTPN1KDM4EMAPTALDH1A1NFKB1
SCHEMBL19076177 0.80 ALDH1A1 (0.56) CYP1A2CYP1A1CYP1B1KDM1AHDAC1
SCHEMBL6841312 0.79 NAPRT (0.54) CYP1A2CYP1A1CYP1B1KDM1AHDAC1
SCHEMBL6841311 0.79 NAPRT (0.54) CYP1A2CYP1A1CYP1B1KDM1AHDAC1
SCHEMBL6641242 0.78 MAPK1 (0.51) CYP1A2CYP1A1CYP1B1KDM1AHDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040157919-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use WU YONG-QIAN (US) 2004-08-12 US disclosed
US-6656971-B2 Non-peptidic small organic compounds having an affinity for cyclophilin (CyP)-type immunophilins; inhibiting their peptidyl-prolyl isomerase activity; treating variety of medical conditions GUILFORD PHARMACEUTICALS INC. 2003-12-02 US disclosed
EP-1360173-A2 TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2003-11-12 EP disclosed
US-20020165275-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use GUILFORD PHARMACEUTICALS INC. 2002-11-07 US disclosed
WO-2002059080-A2 TRISUBSTITUTED CARBOCYCLIC CYCLOPHILIN BINDING COMPOUNDS AND THEIR USE GUILFORD PHARMACEUTICALS INC. (US) 2002-08-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157919-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use FKBP2, PPIG, FKBP8 CYP1A2 27/4885CYP1A1 69/4885CYP1B1 30/4885
US-20020165275-A1 Trisubstituted carbocyclic cyclophilin binding compounds and their use FKBP2, PPIG, FKBP8 CYP1A2 27/4885CYP1A1 69/4885CYP1B1 30/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.